NCT03926143 2023-08-04A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine StudiesBayerPhase 2 Terminated9 enrolled 10 charts
NCT02610140 2020-11-04Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)BayerPhase 2 Completed248 enrolled 23 charts
NCT02639091 2019-11-07Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid TumorsBayerPhase 1 Completed36 enrolled